Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIFEST Clinical Trial
23. Mai 2019 10:28 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 23, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Presents Poster on Studies of CPI-0209 in Bladder Cancer at AACR Meeting
20. Mai 2019 07:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Dr. Patricia Keller, Senior Scientist at Constellation...
Constellation Pharmaceuticals Provides Interim Update of Data for CPI-0610 in ASCO and EHA Abstracts
16. Mai 2019 09:00 ET
|
Constellation Pharmaceuticals , Inc.
Data published in two abstracts suggest that CPI-0610 may have potential disease-modifying effects in treating myelofibrosis All ten evaluable patients experienced spleen volume reductions...
Constellation Pharmaceuticals Announces First-Quarter 2019 Financial Results
08. Mai 2019 16:15 ET
|
Constellation Pharmaceuticals , Inc.
Company to present an interim update of data from the MANIFEST clinical trial of CPI-0610 at ASCO on June 3 and at EHA on June 15Related investor event at ASCO to be held on June 4 ...
Constellation Pharmaceuticals to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day
19. April 2019 08:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., April 19, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial of CPI-1205 at AACR Meeting
01. April 2019 13:00 ET
|
Constellation Pharmaceuticals , Inc.
Clinical activity of CPI-1205 was seen in subsets of advanced metastatic castration-resistant prostate cancer (mCRPC) patientsRecently initiated Phase 2 portion of ProSTAR includes randomized testing...
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial Results
14. März 2019 17:24 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...
Constellation Pharmaceuticals to Present at Upcoming Investor Conference
06. März 2019 14:35 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...
Constellation Pharmaceuticals Appoints Jessica Christo as Chief Product Development Officer
04. März 2019 07:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...
Constellation Pharmaceuticals to Present at Upcoming Investor Conferences
22. Februar 2019 13:24 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...